Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 24 amino acid residues in defined sequence
Patent
1989-11-13
1994-02-01
Lee, Lester L.
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
24 amino acid residues in defined sequence
C07K 710, A61K 3702
Patent
active
052833208
ABSTRACT:
Peptides corresponding to epitopes of HTLV-2 proteins are provided. These peptides are immunologically reactive with HTLV-2 specific antibodies. Several of the peptides are sufficiently unreactive to antibodies to HTLV-1 to distinguish between antibodies which recognize HTLV-1 and those which recognize HTLV-2. Thus HTLV-1 infections can be distinguished from HTLV-2 infections. The peptides are useful in assays for detection of HTLV-2 infection or exposure. The peptides are also useful as vaccine compositions against HTLV-2. Antibodies generated in response to immunization by the peptides are also provided.
REFERENCES:
Seiki, et al, Proc. Natl. Acad. Sci., vol. 80, pp. 3618-3622, 1983.
Perkins, et al, Science, pp. 421-424, 1984.
Barany et al., "Solid Phase Peptide Synthesis", in: The Peptides, vol. 2, Academic Press, Inc. pp. 1-284 (1979).
Cabradilla et al., "Serodiagnosis of Antibodies to the Human AIDS Retrovirus With a Bacterially Synthesized env Polypeptide", Bio/technology, 4:128-133 (1986).
Chang et al., "Detection of Antibodies to Human T-cell Lymphotropic Virus-III (HTLV-III) With an Immunoassay Employing a Recombinant Escherichia coli-Derived Viral Antigenic Peptide", Bio/technology, 3:905-909 (1985).
Erickson et al., "Solid Phase Peptide Synthesis", in: The Proteins, 3rd Edition, vol. 2, Academic Press Inc., Chapter 3 pp. 255-527 (1976).
Gallo et al., "Comparison of Immunofluorescence, Enzyme Immunoassay, and Western Blot (Immunoblot) Methods for Detection of Antibody to Human T-Cell Leukemia Virus Type 1", J. Clin. Micro., 26:1487-1491 (1988).
Gurtler et al., "Sensitivity and Specificity of Commercial ELISA Kits for Screening Anti-LAV/HTLV III", J. Virol. Met., 15:11-23 (1987).
Kieny et al., "AIDS VIRUS env Protein Expressed From a Recombinant Vaccinia Virus", Bio/technology, 4:790-795 (1986).
Lee et al., "High Rate of HTLV-II Infection in Seropositive IV Drug Abusers in New Orleans", Science, 244:471-475 (1989).
Lerner, "Antibodies of Predetermined Specificity in Biology and Medicine", Advances in Immunol., 36:1-44 (1984).
Lerner et al., "The Development of Synthetic Vaccines", in: The Biology of Immunologic Disease, Dixon and Fisher eds. Sinaur Associates Inc. MA, pp. 331-338 (1983).
Marx, "Leukemia Virus Linked to Nerve Disease", Science, 236: 1059-1061 (1987).
Putney et al., "HTLV-III/LAV-Neutralizing Antibodies to an E. coli-Produced Fragment of the Virus Envelope", Science, 234: 1392-1395 (1986).
Robert-Guroff et al., "Prevalence of Antibodies to HTLV-1, -II and -III in Intravenous Drug Abusers From an AIDS Endemic Region", J.A.M.A., 255:3133-3137 (1986).
Rodgers-Johnson et al., "HTLV-I and HTLV-III Antibodies and Tropical Spastic Paraperesis", Lancet, Nov. 30, 1985 pp. 1247-1248.
Rosenblatt et al., "Integrated Human T-Cell Leukemia Virus II Genome in CD8+ T Cells From a Patient With Atypical Hairy Cell Leukemia: Evidence for Distinct T and B Cell Lymphoproliferative Disorders", Blood, 71:363-369 (1988).
Rosenblatt et al., "A Second Isolate of HTLV-II Associated with Atypical Hairy-Cell Leukemia", New Engl. J. Med., 315:372-377 (1986).
Sarngadharan et al., "Human T-cell Leukemia Viruses", Virology, Chapter 58:1345-1371 (1985).
Shaw et al., "Human T-Cell Leukemia Virus: Its Discovery and Role in Leukemogenesis and Immunosuppression", Year Book Medical Publishers, Inc., pp. 1-27 (1984).
Shimotohno et al., "Complete Nucelotide Sequence of an Infections Clone of Human T-Cell Leukemia Virus Type II: An open Readinjg Frame for the Protease Gene", Proc. Natl. Acad. Sci. USA, 82:3101-3105 (1985).
Tedder et al., "Low Prevalance in the UK of HTLV-I and HTLV-II Infection in Subjects with AIDS, With Extended Lymphadenopathy, and at Risk of AIDS", Lancet, Jul. 21, 1984 p. 125-127.
Vernant et al., "Endemic Tropical Spastic Paraparesis Associated With Human T-Lymphotropic Virus Type I: A Clinical and Seroepidemiological Study of 25 Cases", Ann. Neurol., 21:123-130 (1987).
Horal Peter
Jeansson Stig
Rymo Lars
Svennerholm Bo
Vahlne Anders
Lee Lester L.
Marshall S. G.
Syntello AB
LandOfFree
Peptides for HTLV-2 infection diagnosis of, therapy for, vaccina does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides for HTLV-2 infection diagnosis of, therapy for, vaccina, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides for HTLV-2 infection diagnosis of, therapy for, vaccina will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-580497